Monitor pipeline catalysts: frataxin data in H2 2026 for DT-216P2 and FECD biomarker data for DT-168 could drive significant moves. Cash runway into 2029 reduces near-term dilution risk.
Price Chart
Executive Summary
Design Therapeutics reported Q1 2026 net loss per share of $(0.29), beating consensus of $(0.33) by 12%. The company highlighted progress in its GeneTAC portfolio with ongoing clinical trials for Friedreich ataxia, Fuchs endothelial corneal dystrophy, and myotonic dystrophy type-1. Cash and securities of $222.8M provide runway into 2029.
Key Financial Metrics
Key Facts
- Q1 2026 net loss per share $(0.29), consensus $(0.33) (beat by 12%)
- Cash and securities $222.8M as of March 31, 2026
- RESTORE-FA trial for DT-216P2 ongoing; data update expected H2 2026
- Phase 2 FECD trial of DT-168 ongoing; data expected H2 2026
- DT-818 Phase 1 MAD trial expected to start H1 2026
- David Shapiro appointed to board of directors in March 2026
Financial Impact
Net loss of $17.6M, EPS beat of $0.04 vs consensus
Risk Factors
- Clinical trial failures or delays could impact stock
- No approved products; pre-revenue company
- Potential equity dilution if need for additional capital arises
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3283154 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 3, 2026 12w ago | 8-K | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
Aug 3, 2026 12w ago | Press Release | $12.76 $15.09 | ▲ +18.26% | ▲ +17.02% | $10.40 (−18.50%) |
May 18, 2026 23w ago | 8-K | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 18, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
May 17, 2026 23w ago | Press Release | $10.70 $10.72 | ▲ +0.19% | ▼ −1.39% | $10.40 (−2.80%) |
Apr 28, 2026 25w ago | Press Release | $15.79 $11.10 | ▼ −29.70% | ▼ −35.16% | $10.40 (−34.14%) |
Apr 23, 2026 26w ago | DEFA14A | $12.53 $11.01 | ▼ −12.13% | ▼ −16.16% | $10.40 (−17.00%) |
Apr 1, 2026 29w ago | 3 | $11.23 $13.60 | ▲ +21.10% | ▲ +11.23% | $10.40 (−7.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers